Edison attended the 2017 American Society of Clinical Oncology (ASCO)Annual Meeting in Chicago, US, on 2-6 June.
This year the main focus was
chimeric antigen receptor (CAR) T Cell therapies, in particular CARTs
targeting BCMA from Bluebird Bio and Nanjing Legend; and immunooncology
(IO) combinations such as IDO1/PD-1 inhibitors and new targets
like LAG3 and GITR.
Targeted therapies also took centre stage, particularly
Loxo’s larotrectinib and AstraZeneca’s Lynparza, along with Roche’s
APHINITY data. Finally, we also present data from companies under our
coverage: Hutchison China MediTech, MorphoSys, PharmaMar, Prima
Biomed and Viralytics.
PharmaMar presented data from a mid-stage study in 97 patients with advanced endometrial
cancer (abstract 5586).
Lurbinectedin (PM01183) was evaluated as monotherapy and in two doses
in combination with doxorubicin and in combination with paclitaxel. The best ORR was seen in
combination with doxorubicin, with 28% ORR in Cohort A (3-5 mg flat dose of lurbin. plus dox 50
mg/m2 both at day 1) and 44% ORR in Cohort B (2 mg/m2 of lurbin. plus dox 40 mg/m2 both at day
1). DCR was 85% and 83% respectively. Median PFS was 7.8 months and 7.7 months respectively.
On the back of these data the company plans to initiate a Phase III trial for US registration.
Additionally, PharmaMar presented data from Yondelis (trabectedin) and lurbinectedin in BRACA1
and BRACA2 positive breast cancer, Yondelis in mesothelioma and soft tissue sarcoma and
Yondelis in AML and r/r myelodysplastic syndrome (MDS).